Objective: The primary objective of this study was to re-evaluate the feasibility of docetaxel at doses of up to 75 mg/m 2 in Japanese patients with previously treated non-small cell lung cancer. Methods: Patients received escalated doses of docetaxel at 70 mg/m 2 (level 1) or 75 mg/m 2 (level 2) every 3 weeks until disease progression or unacceptable toxicities. Dose escalation was decided on the basis of dose-limiting toxicity in the first cycle of chemotherapy.
INTRODUCTION
Currently in Japan, several agents (ex. docetaxel, pemetrexed, gefitinib, erlotinib or crizotinib) are recommended for use in patients with advanced or recurrent NSCLC that has progressed after platinum-based first-line chemotherapy based on the results of the clinical trials (1 -6) . Among these agents, gefitinib and erlotinib are epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and so they are used mainly for patients who have EGFR mutations (7 -9) . Because crizotinib is also a receptor tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), it is only used for patients who have ALK rearrangements (10) . With regard to pemetrexed, it has recently become clear that some specific populations can benefit from the agent, for example those with non-squamous histology or low expression of thymidine synthase (11, 12) . Furthermore, pemetrexed has recently been used for both first-line chemotherapy and maintenance therapy (13) . Therefore, the EGFR-TKIs, crizotinib and pemetrexed are used for limited populations of patients who can receive second-or third-line chemotherapies.
In contrast to such agents, docetaxel shows active cytotoxicity against various histological types of NSCLC by inhibiting microtubule depolymerization and promoting tubulin assembly in the M phase of the cell cycle, causing the cells to cease dividing. Docetaxel is usually administered at a dose of 75 mg/m 2 every 3 weeks in Western countries and almost in all Asian countries based on the results of two randomized controlled trials and a randomized phase II trial (1, 2, 14) . In Japan, on the other hand, docetaxel has been administered at a relatively lower dose of 60 mg/m 2 in both clinical trials and clinical practice based on the recommended dose determined in a domestic phase I trial. However, the Japanese and Western studies demonstrated no significant difference in the pharmacokinetics (PK) of docetaxel (15) .
Docetaxel is one of the most important cytotoxic agents for the treatment of NSCLC and is used as the reference regimen in clinical trials for previously treated NSCLC. Therefore, the difference in the recommended dose between Western and Japanese patients is a major problem for Japan when participating in global trials. The reason for the discrepancy in the maximum tolerated and recommended doses in comparison with Western studies remains unknown. Furthermore, no previously reported study has re-evaluated the safety, feasibility and efficacy of docetacel at a dose of 75 mg/m 2 , which is the global standard, since the drug was approved in Japan in 1997 (15) . Therefore, we conducted the present study to reassess the safety, feasibility and efficacy of docetaxel at doses of up to 75 mg/m 2 in Japanese patients with previously treated NSCLC.
PATIENTS AND METHODS

STUDY DESIGN
The primary objective of this study was to re-evaluate the feasibility of docetaxel at doses of up to 75 mg/m 2 for Japanese patients with previously treated NSCLC.
Patients were divided into two docetaxel dose levels. At dose level 1, 6 patients received a dose of 70 mg/m 2 . If three of these six patients experienced dose-limiting toxicity (DLT), dose escalation was terminated. If two of the patients or fewer experienced DLT, dose escalation was continued to the next level. At dose level 2, initially, the first six patients received docetaxel at 75 mg/m 2 . If three of them experienced DLT, the study was terminated. If DLT was observed in 2 of the first 6 patients or fewer, additional patients, up to a maximum of 20, were enrolled to receive docetaxel at 75 mg/m 2 . Dose escalation was decided according to whether DLT occurred only in the first cycle of chemotherapy, although toxicities observed after the second cycle were taken into consideration in the final feasibility assessment.
PATIENT SELECTION
Patients with histologically or cytologically documented advanced or recurrent NSCLC, who had previously undergone platinum-based chemotherapy not including docetaxelcontaining regimens, were eligible for study entry. An interval of at least 4 weeks from previous chemotherapy was required. Radiation therapy to a target lesion was allowed unless there was obvious disease progression in that lesion. Each patient was required to meet the following criteria: having measurable lesions; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1; age 75 years or less; SpO 2 94%; normal 12-lead ECG; adequate bone marrow reserve [white blood cell (WBC) count 4000/ml, absolute neutrophil count (ANC) 2000/ml, platelet count 100 000/ml and hemoglobin 9.0 mg/dl]; and adequate hepatic and renal function (creatinine 1.5 mg/dl, total bilirubin 1.5 mg/dl and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels 2.5 times upper limit of normal).
The main exclusion criteria were active concomitant malignancy, congestive heart failure, uncontrolled angina pectoris, arrhythmia, hypertension, uncontrolled diabetes, symptomatic infectious disease, severe hemorrhage/bleeding, pulmonary fibrosis or interstitial pneumonia, obstructive bowel disease or severe diarrhea, symptomatic peripheral effusion, cardiac effusion and ascites, Grade 2 peripheral neuropathy, symptomatic brain metastasis and pregnancy or breast feeding.
The study complied with the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol was approved by the institutional review board at Kurume University. All patients gave written informed consent prior to registration.
This study was registered with UMIN (University Hospital Medical Information Network in Japan), number UMIN 000003021.
STUDY TREATMENT
All patients received intravenous infusion of docetaxel over at least 60 min (70 or 75 mg/m 2 ) every 3 weeks. Treatment was to be performed until disease progression, unacceptable toxicity or until the patients or the investigator requested treatment discontinuation. Subsequent cycles of treatment were withheld until the following criteria were satisfied: ECOG PS 1, ANC 2000/ml, platelet count 100 000/ml, total bilirubin 1.5 mg/dl, AST and ALT levels 2.5 times upper limit of normal, creatinine 1.5 mg/dl, SpO 2 94%, absence of active infection and other non-hematological toxicity Grade 2. If these criteria were unsatisfied within 35 days from Day 1 of the current cycle, the patient was removed from the study. (4) 339 of granulocyte colony-stimulating factor (G-CSF) was not allowed at any time during the study. All patients underwent comprehensive baseline assessments including clinical laboratory tests and imaging studies. During the first cycle, clinical laboratory tests were performed at least twice a week. Patients also received follow-up assessments and monitoring at regular intervals thereafter. Toxicity evaluations were based on the Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE v3.0) (16) .
DEFINITION OF DLT
DLTs were defined as a toxicity occurring in Cycle 1 that met one of the following criteria and for which a causal relationship with docetaxel could not be ruled out: Grade 4 neutropenia lasting 7 days or longer, febrile neutropenia (FN), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia that required platelet transfusion or was associated with bleeding, Grade 3 or 4 non-hematological toxicity (following events were to be DLT if the event did not recover to Grade 2 despite standard/optimal supportive treatment: nausea, vomiting, anorexia, fatigue, constipation, diarrhea or transient electrolyte abnormality). If the patients experienced toxicities that met the DLT criteria, treatment doses were modified in subsequent courses.
SAFETY AND EFFICACY EVALUATION
All patients who received at least one dose of the study treatment were included in the safety and efficacy analysis. The incidence of adverse events was calculated for each dose group. The percentage decrease in ANC was also calculated from the baseline and nadir ANC. The efficacy endpoints were tumor response, progression-free survival (PFS) and overall survival (OS). Tumor response was evaluated according to the RECIST guideline and the distribution of the best overall responses was summarized in patients with target lesions (17) . PFS was defined as the time from enrollment to the date of confirmation of progressive disease (PD) or the date of death from any cause, whichever was earlier. OS was defined as the time from registration until death from any cause. Patients not known to have died and to have had progression were censored at the date of the last progression-free assessment. KaplanMeier (K -M) methods were used for PFS and OS analyses. This included generating the K -M curve and determining the median with the 95% confidence interval. The survival data were cut off on 31 January 2013.
RESULTS
PATIENT CHARACTERISTICS
Between January 2010 and July 2012, 26 patients were enrolled into this study. Table 1 shows the characteristics of these patients. Twenty-three patients were male and three were female. The median age of the participants overall was 66 years (range 35 -74 years). The majority of the patients had a PS of 0. Histologically, there were 19 adenocarcinomas and 6 squamous cell carcinomas. All but three patients received docetaxel as the second-line treatment. Seven of the 19 adenocarcinomas harbored EGFR mutations.
DOSE ESCALATION
The profiles of major toxicities and DLTs observed in Cycle 1 are shown in Table 2 . At dose level 1, a DLT was observed in only one of six patients: Grade 3 FN. Apart from this DLT case, three patients at this dose level developed Grade 4 neutropenia, but the neutrophil count in these patients recovered rapidly without the use of G-CSF. Non-hematological toxicities were generally mild. The dose of docetaxel was then escalated to 75 mg/m 2 (level 2). At dose level 2, only one of the first six patients developed DLT: Grade 3 FN. Although all of the first six patients as well as this DLT case also developed Grade 3 or 4 neutropenia, the neutrophil count in these patients recovered rapidly without the use of G-CSF, similarly to level 1. Non-hematological toxicities were also generally mild. Therefore, an additional 14 patients were assigned to this dose level. In total, 20 patients were administered docetaxel at 75 mg/m 2 .
TOXICITIES
The profiles of major toxicities and severe toxicities observed during the entire treatment period are shown in Tables 3 and  4 . The hematological toxicities reaching Grade 3 were Ad, adenocarcinoma; Sq, squamous cell carcinoma; Ad-Sq, adenosquamous cell carcinoma; EGFR, epidermal growth factor receptor.
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Feasibility re-evaluation of 75 mg/m 2 docetaxel Table 2 . Profile of major toxicities during the DLT period (Cycle 1)
Toxicity grade  Toxicity grade  Toxicity grade   G1  G2  G3  G4  G1  G2  G3  G4  G2/ Although more than half of the patients experienced fatigue and anorexia, these were mostly transient and improved rapidly with standard/optimal supportive treatment. Other observed toxicities were predictable from the safety profile of decetaxel, and were well managed. There was one treatment-related death in a 68-year-old man with adenocarcinoma that had progressed after initial chemoradiotherapy. He developed FN in the first cycle and gastric A total of nine patients were withdrawn from the study due to treatment-related toxicities. Two patients discontinued because of a dose delay due to non-recovery of the neutrophil count and worsening PS, respectively. Three patients refused the study treatment due to maximum Grade 2 fatigue. Two patients developed ILD: one died as described above and the other recovered. The remaining two patients were withdrawn from the study by the investigators because of Grade 2 but refractory limb edema and subungual abscess, respectively.
For the 20 patients who received a dose of 75 mg/m 2 , only 62% of the cycles (58 of 94 cycles) could be delivered at the initial dose in comparison with 89% (33 of 37 cycles) in the 6 patients who received a dose of 70 mg/m 2 .
EFFICACY
There were four partial responses (one patient at dose level 1 and three patients at dose level 2) and no complete responses, yielding an overall response rate of 15.4%. One patient at dose level 2 was not evaluable for response because of ILD in Cycle 2. The median number of treatment cycles for the patients overall was 4 (range, 2 -22 cycles). All 26 patients were assessable for PFS and OS. After a median follow-up period of 12.5 months (range, 3.2 -36.0 months), 12 patients were still alive. The median PFS of the patients overall was 4.0 months (95% CI 1.4 -6.6 months; Fig. 1A) , and that for patients at dose level 1 and dose level 2 was 3.3 and 4.0 months, respectively. The median OS for all patients was 14.6 months (95% CI 2.9-26.2 months; Fig. 1B ).
POST-DISCONTINUATION CHEMOTHERAPY
Except for 3 patients who did not show disease progression, 20 (87%) of the 23 patients received third-or fourth-line chemotherapy. Among the seven patients who had EGFR mutations, three had already received EGFR-TKI as the firstor second-line chemotherapy before entering the study and the rest received EGFR-TKIs after failure of the study treatment. Among patients with wild-type EGFR or an unknown EGFR mutation status, nine received erlotinib after failure of the study treatment.
DISCUSSION
This is, to our knowledge, the only study to have re-evaluated the feasibility of docetaxel at doses of up to 75 mg/m 2 in Japanese patients with previously treated NSCLC. Even at 70 mg/m 2 , no previous report has documented the safety and efficacy of docetaxel prospectively, and for this reason we decided to start the present study at 70 mg/m 2 .
As DLT was observed in 1 patient at dose level 1 and in 1 of the first 6 patients at dose level 2, we were able to accrue 20 patients at dose level 2, as originally planned. At dose level 2, we observed DLT in 6 patients (30%) in the first cycle, including 5 patients with FN. These accounted for less than one-third of the patients at dose level 2. Eight out of the 20 patients (40%) finally developed FN at some point during the treatment period. In addition, because of DLT, another two patients at this dose level required dose reduction to 70 mg/m 2 after the second cycle or later. As a result, only 62% of cycles could be delivered at the initial dose, the rate being very similar to that reported by Shepherd et al. (2) for a dose of 100 mg/m 2 . However, unlike that study, which recorded a 10% early death rate, no early deaths due to toxicity occurred in our study. On the other hand, among 6 patients at dose level 1 and 10 patients at dose level 2 who required dose reduction and received docetaxel at 70 mg/m 2 thereafter, DLT was observed in only 3 of the 16 patients (19%), including 2 with FN during the treatment period. Therefore, docetaxel at an Jpn J Clin Oncol 2014;44 (4) 343 initial dose of 75 mg/m 2 was manageable with dose reduction or appropriate supportive care, although the toxicity seemed to be more severe in these Japanese patients than in previously reported cohorts from other countries.
Severe neutropenia (Grade 3 or 4) was observed in nearly 90% of the patients in this study, being approximately equivalent to the rate documented previously in Japan for a dose of 60 mg/m 2 (18 -20) . However, as shown in Table 5 , the incidence of FN in our patients at a dose of 75 mg/m 2 was clearly higher than that reported previously. FN is a critical toxicity and a potentially life-threatening oncologic emergency. According to the American Society of Clinical Oncology Clinical Practice Guidelines published in 2006, primary prophylactic CSF is recommended when the risk of FN is 20% or higher (21) . However, this does not mean that prophylactic CSF should be used for all patients receiving such a high-risk regimen. The primary consideration is the aim of the treatment, i.e. curative, prolongation of life or palliative. If treatment is not curative, a change to an alternative regimen or dose modification should be considered, rather than using prophylactic CSF. Unfortunately, because chemotherapy is unable to achieve complete cure for advanced or recurrent NSCLC at this time, the role of chemotherapy for these patients is prolongation of life, palliation or symptom control. On the basis of this rationale, we did not use prophylactic CSF for our patients.
In this study we found a considerable difference in the incidence of FN between the two dose levels, even though the difference in dose was only 5 mg/m 2 . Although the reason for this is unclear, it has been reported that docetaxel exposure (i.e. docetaxel clearance) is a significant predictor of Grade 4 neutropenia and FN (22) . Furthermore, Yamamoto et al. (23) have reported that when docetaxel was administered on the basis of body surface area, the interpatient variability in the area under the concentration -time curve (AUC) became large in Japanese patients. In the present study, there was no significant difference in the incidence of Grade 4 neutropenia (ANC , 500) between the two dose levels. However, 10 of 20 patients (50%) in the 75 mg/m 2 group developed an ANC nadir of ,200, whereas only 1 patient in the 70 mg/m 2 group did so (data not shown). Because all patients who developed FN had an ANC nadir of ,200, which significantly increased the likelihood of FN, more patients with a high AUC in the 75 mg/m 2 group developed a lower ANC nadir than those in the 70 mg/m 2 group, and this may have affected the incidence of FN. However, non-hematological toxicities other than FN were mild, and similar in severity to those reported previously in both Japan and Western countries (1,2,18 -20,24) . Therefore, some genetic or other distinctive factors may be associated with FN, and further research is needed.
This study may have had some potential drawbacks in that the number of patients was small and we did not stipulate a specific statistical design, because our main purpose was to re-evaluate the feasibility of the global standard dose of docetaxel on a clinical basis. Moreover, we did not perform PK/pharmacodynamic or pharmacogenomic examinations. Therefore, it is unknown whether ethnic differences could have fully explained the difference in sensitivity to FN at a dose of 75 mg/m 2 . The possibility that the incidence of FN in our study could have been attributable to chance also cannot be ruled out.
In summary, considering the toxicities comprehensively, docetaxel monotherapy at an initial dose of 75 mg/m 2 according to the protocol definition is considered to be feasible for Japanese patients with previously treated NSCLC. However, the administration of docetaxel at 75 mg/m 2 may increase the incidence of FN in Japanese patients. Therefore, it is highly recommended that feasibility should be confirmed beforehand when Japanese patients with NSCLC participate in global studies using docetaxel at 75 mg/m 2 in combination with other agents.
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